Icon

FASLODEX (nda021344)- (250MG/5ML (50MG/ML))

FULVESTRANT ASTRAZENECA
250MG/5ML (50MG/ML)
Yes No
2022-Apr-09 Expired
None None
None No
FASLODEX is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
14 0 14
Total Other Developers 11
Drugs with Suitability No
250MG/5ML (50MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ******** **** *********** *********** ***
****** ******** ****** *** ********* ******, ***. *********** ***** ******* ******, *** *****, ********** (**) *****, ****** ****** (***) ***
****** ******** ****** *** ******** *************** ***., *** *********** **** ******** **, ******, ***** ******** (**) *****, ****** ****** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** *** **** *** ******* ****-****** *********** ************** **.,***. (*** ****) *********** **, ** ***** ****, ******* **** *** *** ********** *********** **** ******* ******, *******, ******* ******, ***** (***) ***
****** ****** ****** *************** ******* ******* *********** **** **. **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***. ******, *********, ** ******, ***** (***) ***
****** **** *** ******** **** *** ******** ************** ***** **., ***. *********** **. *** ****** ***** ****, ***********, ******* ******** ******, ***** (***) ***
****** **** *** ******** *********** ******** ************** **., ***. *** *********** **. ** ******* **., **** ********** ****, ******** ********** *********** ****, ***********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ******* ************ ********, *.*. *********** ***** ** ******* (***. ***. **********), */* - ****. *, **************, *****, ***** (***) ***
****** ******* ****** ***** ******* ****** ************** ***** **., ***. *********** **.* ******* ****, ******** *** ********* *********** ****, ***********, ******* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** ****** **. **,**/*,**,**/*,** ** **, *******-***** *.*. **. **, ***. ****** ******, *******-*********, ***:******, ****-*********, *********, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ******** ***, **** **. ****/****, ******* - *********, ****** - *****, ********, ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.